Icon Plc (ICLR)
NASDAQ:ICLR
Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$119.68
-$3.85(-1.73%)
At close: 4:00 PM EST
$119.68
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$66.57 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)1.35M
Market Cap
$10.42B
Enterprise Value$13.33B
Total Cash (Recent Filing)$647.29M
Total Debt (Recent Filing)$3.56B
Price to Earnings (P/E)47.2
Beta1.18
Next Earnings
Jul 29, 2026EPS Estimate
2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.85
Shares Outstanding76,567,320
10 Day Avg. Volume1,155,407
30 Day Avg. Volume1,349,605
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit6.48
Enterprise Value/Ebitda10.25
Forecast
1Y Price Target
$147.55Price Target Upside23.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)10.69
Revenue Forecast (FY)$7.98B
Bulls Say, Bears Say
Bulls Say
Backlog And Book-to-BillA $21.8B backlog and a 1.36 book-to-bill provide durable revenue visibility and multi-year contract conversion. This reduces near-term cyclicality in sponsor R&D spending and supports predictable revenue ramp as awarded work converts to future services over several quarters to years.
Operating Cash Flow & Free Cash FlowStrong absolute OCF and FCF demonstrate the business’s ability to convert services into cash, enabling debt repayment, buybacks and reinvestment. Sustained cash generation supports financial flexibility and funds investments in capacity and technology over the medium term.
Improving Leverage / Balance-Sheet ResilienceA declining debt burden and substantial equity provide balance-sheet resilience, lowering refinancing and covenant risk. Improved leverage enhances capacity to fund strategic investments, absorb shocks, and execute remediation or growth projects without jeopardizing liquidity.
Bears Say
Slowing Revenue GrowthTop-line momentum has decelerated to near-flat growth, reducing the company’s ability to expand share organically. Over a multi-quarter horizon, tepid revenue growth constrains scale economies and limits room for margin recovery absent new high-growth services or market share gains.
Margin Compression And Weaker Cash ConversionMarked margin deterioration and weaker cash conversion in 2025 indicate reduced operating leverage and/or rising cost pressures. Persistently lower margins would erode free cash flow, limit reinvestment capacity and reduce resilience against cyclical drops in sponsor R&D spend.
Financial Controls And Regulatory/Listing RiskRestatements and material internal-control weaknesses are structural governance risks that can impair investor trust, elevate regulatory scrutiny, and divert management focus. A Nasdaq deficiency notice raises the prospect of compliance actions that could constrain capital-markets flexibility.
Icon News
ICLR FAQ
What was Icon Plc’s price range in the past 12 months?
Icon Plc lowest stock price was $66.57 and its highest was $211.00 in the past 12 months.
What is Icon Plc’s market cap?
Icon Plc’s market cap is $10.42B.
When is Icon Plc’s upcoming earnings report date?
Icon Plc’s upcoming earnings report date is Jul 29, 2026 which is in 56 days.
How were Icon Plc’s earnings last quarter?
Currently, no data Available
Is Icon Plc overvalued?
According to Wall Street analysts Icon Plc’s price is currently Undervalued.
Does Icon Plc pay dividends?
Icon Plc does not currently pay dividends.
What is Icon Plc’s EPS estimate?
Icon Plc’s EPS estimate is 2.56.
How many shares outstanding does Icon Plc have?
Icon Plc has 76,567,320 shares outstanding.
What happened to Icon Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Icon Plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$147.55 (23.28% Upside)
$147.55 (23.28% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $61.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 53%
Bearish news 53%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.94%
12-Months-Change
Fundamentals
Return on Equity
2.44%
Trailing 12-Months
Asset Growth
-3.60%
Trailing 12-Months
Company Description
Icon Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Stock 12 Month Forecast
Average Price Target
$147.55
▲(23.28% Upside)
Technical Analysis
Ownership Overview
― Insiders
34.76% Mutual Funds
57.26% Other Institutional Investors
5.58% Public Companies and
Individual Investors